Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
Ignace Vergote, Els Van Nieuwenhuysen, Antonio Casado, Annouschka Laenen, Domenica Lorusso, Elena Ioana Braicu, E.M. Guerra-Alía, Paolo Zola, Pauline Wimberger, Philip R. Debruyne, E. Falcó, Annamaria Ferrero, Mustafa Zelal Muallem, Joseph Kerger, Elena García‐Martínez, Sandro Pignata, Jalid Sehouli, Toon Van Gorp, Christine Gennigens, M.J. Rubio
Topics & Concepts
MedicineCarboplatinClinical endpointNintedanibInternal medicineNeutropeniaPazopanibAdverse effectCervical cancerBevacizumabOncologyFebrile neutropeniaPhases of clinical researchResponse Evaluation Criteria in Solid TumorsPopulationGastroenterologySurgeryRandomized controlled trialCancerChemotherapyCisplatinEnvironmental healthIdiopathic pulmonary fibrosisLungSunitinibEndometrial and Cervical Cancer TreatmentsHER2/EGFR in Cancer ResearchAngiogenesis and VEGF in Cancer